Gilead (GILD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Gilead Sciences, Inc. GILD announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European ...

Gilead Sciences, Inc. (GILD) stock saw a decline, ending the day at $91.86 which represents a decrease of $-0.52 or -0.56% from the prior close of $92.38. The stock opened at $91.66 and touched a low ...

Buying $100 In GILD: If an investor had bought $100 of GILD stock 20 years ago, it would be worth $1,075.53 today based on a ...

Some 90% of investigational drugs fail—and success rates are even more dire in the neuro space. Here, BioSpace looks at five ...

UK-based NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announced the appointment of Michael ...

In a report released today, Joseph Catanzaro from Piper Sandler maintained a Buy rating on Repare Therapeutics (RPTX – Research Report), with a ...

The broad U.S. stock market posted solid gains that saw a reversal of trends from the first half of the year. Click here to read the full commentary.

Spearheading pharmaceutical firms involving Intercept Pharmaceuticals, Bristol-Myers Squibb, Gilead Sciences, and Novo Nordisk, are at the vanguard of diligently included in clinical trials and ...

New research suggests that activation of the PPARδ protein, which is linked to inflammation, could treat or prevent diabetic cardiomyopathy, a serious heart condition.

New research revealed tumor mutational burden was linked to improved event-free survival with pembrolizumab in early TNBC, ...

Pharmaceutical companies have an untapped potential to transform global health, but they cannot act alone. Governments, NGOs, ...